An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)
NCT00826878
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
17
Enrollment
INDUSTRY
Sponsor class
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG:
Tivozanib (AV-951)
Sponsor
AVEO Pharmaceuticals, Inc.